Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 6Neoplasms 2Pancreatic Neoplasms 1Liver Cirrhosis 1Infections 1Hepatitis D 1Hepatitis C, Chronic 1Hepatitis C 1Hepatitis B, Chronic 1Hepatitis B 1Fibrosis 1Esophageal and Gastric Varices 1Colonic Neoplasms 1

Interventions

Ribavirin 3sofosbuvir-velpatasvir drug combination 2elbasvir-grazoprevir drug combination 2Sorafenib 2telaprevir 1rocakinogene sifuplasmid 1pembrolizumab 1peginterferon alfa-2a 1navitoclax 1menatetrenone 1hepatitis C immune globulin, human 1grazoprevir 1elbasvir 1Sofosbuvir 1Rapid Diagnostic Tests 1Raltegravir Potassium 1Patient Navigation 1Mass Screening 1Introns 1Immunoglobulin G 1Immunoenzyme Techniques 1Hypothermia, Induced 1Enzyme-Linked Immunosorbent Assay 1Chromatography, High Pressure Liquid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hepatitis C × peginterferon alfa-2a × Gastrointestinal × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡